Beijing, China, November 11, 2025 — Today, MSD China R&D Center successfully hosted the inaugural MSD R&D China Science Day in Beijing. The event brought together guests from research institutes, medical institutions, biotech enterprises and the financial sector to explore new opportunities in pharmaceutical innovation, clinical development and industry-academia-research collaboration. During the event, MSD R&D (China) Co., Ltd. and Myeloid Cure signed a letter of intent for cooperation, further deepening MSD's China innovation and internationalization strategy and fulfilling its commitment to local roots and global patient impact.

 MSD · Inaugural MSD R&D China Science Day & Innovation Collaboration Signing Ceremony

Overview of MSD China R&D

As a key innovation initiative under MSD's global R&D network, the MSD R&D China Innovation Collaboration Center (MCICC) was officially launched on November 1, 2024. It is dedicated to building an open, agile and efficient innovation collaboration platform focused on high-potential early-stage projects, integrating MSD's global scientific resources with the strengths of China's local innovation ecosystem to advance high-quality clinical translation from "discovered in China" to "applied globally". As China-originated innovations continue to demonstrate global influence, the establishment of MCICC marks MSD's strategic deepening of partnerships with China's scientific community and biopharmaceutical industry.

Leveraging this platform, MSD collaborates with outstanding local partners to advance breakthrough innovations and accelerate their development into globally accessible treatments, bringing benefits to patients sooner. Over the past year, MCICC has built an extensive cooperation network with domestic biotech companies, investment institutions, industrial parks, hospitals and universities; while advancing project evaluation and clinical development partnerships, it has continuously shared international experience and collaboration opportunities with industry stakeholders, fostering two-way connectivity between global R&D resources and China's innovation ecosystem.

As the annual flagship event of MSD R&D China, the Science Day aims to create a high-level scientific exchange platform, deepen dialogue and collaboration between MSD and China's innovation ecosystem, accelerate the translation of innovations, and expand patient access. Through this platform, MSD seeks to strengthen synergy with local innovation forces and integrate into China's dynamic innovation landscape.

Headquartered in Beijing, MSD China R&D Center has R&D teams in Shanghai, Guangzhou, Chengdu and Wuhan, with research focus areas including oncology, vaccines, anti-infectives, cardiovascular and metabolic diseases, respiratory diseases, immunology, neuroscience and ophthalmology. Its oncology portfolio covers more than 20 cancer types, including several high-incidence cancers in China. To date, MSD has brought more than 80 innovative medicines, vaccines, new indications and companion diagnostics to China, continuously addressing unmet local clinical needs.

About Myeloid Cure

Myeloid Cure has been deeply engaged in source innovative drug R&D targeting macrophages for years, and has built a robust, highly competitive innovative pipeline matrix across critical disease areas including autoimmune diseases and oncology. As a core component of the immune system, macrophages play a pivotal role in the pathogenesis of multiple diseases, making macrophage-targeted drug discovery a key frontier for tackling intractable conditions. With its deep expertise and cutting-edge advancements in the field, Myeloid Cure has developed multiple proprietary innovative drug candidates, earning widespread industry recognition for its R&D capabilities and innovative outputs.

In recent years, China's biopharmaceutical industry has thrived under supportive policy frameworks, creating a favorable environment for local enterprises to engage in international cooperation. Myeloid Cure's intended partnership with MSD is a vivid reflection of the growing innovation prowess of China's biopharmaceutical sector.

Looking ahead, Myeloid Cure will uphold its innovation-driven philosophy, continue to deepen macrophage-focused R&D, and use this intended collaboration as a springboard to expand international partnerships and accelerate the global translation of local innovations. Through in-depth engagement with global pharmaceutical leaders such as MSD, Myeloid Cure aims to further elevate its R&D capabilities and global perspective, bring China-originated original medicines to the world stage, and contribute Chinese innovation to global patient health and well-being.